A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a ...
Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, reduced the risk of tumor recurrence or death by 49% over five years in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results